{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T23:05:57Z","timestamp":1780009557332,"version":"3.53.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01808-4","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T22:55:38Z","timestamp":1780008938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating tumor DNA in breast cancer: updates from SABCS 2025"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4263-7272","authenticated-orcid":false,"given":"Iris","family":"Zhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Vasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shridar","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1808_CR1","doi-asserted-by":"crossref","unstructured":"Bidard F, Mayer EL, Park Y, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Brufsky A, Fasching P, Nowecki Z, Pascual J, Gal-Yam E, Chung W, Im S, Zambelli A, Dalenc F, Oliveira M, Fox S, Selvi Miralles M, Morrow C, Huang Bartlett C. N. C. Turner. Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4\/6 inhibitor (CDK4\/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+\/HER2- advanced breast cancer (ABC) [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr RF7-03.","DOI":"10.1158\/1557-3265.SABCS25-RF7-03"},{"key":"1808_CR2","doi-asserted-by":"crossref","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Chung W-P, Cort\u00e9s J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Lerzo G, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park Y, Sohn J, Toi M, Zhukova L, DeBruin E, Nardone A, Spencer A, Fulford M, Schiavon G. H. S. Rugo. Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr RF7-05.","DOI":"10.1158\/1557-3265.SABCS25-RF7-05"},{"key":"1808_CR3","doi-asserted-by":"crossref","unstructured":"Hilz S, Turner N, Kalinsky K, Loibl S, Jhaveri K, Im S, Saura C, Schmid P, Loi S, Stout T, Song C, Hutchinson K. D. Juric. Molecular features of response to palbociclib\u2009+\u2009fulvestrant\u2009\u00b1\u2009inavolisib in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer as assessed from baseline circulating tumor DNA in the pivotal Phase 3 INAVO120 trial [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD5-09.","DOI":"10.1158\/1557-3265.SABCS25-PD5-09"},{"key":"1808_CR4","doi-asserted-by":"crossref","unstructured":"BIDARD F, Jhaveri K, Kim S, Tokunaga E, Aftimos P, Saura C, O\u2019Shaughnessy J, Harbeck N, Curigliano G, Llombart-Cussac A, Lim E, Im S, Bando H, Neven P, Estrem ST, Nguyen B, Cao S, Makena M, Desai B, Carey LA, Circulating Tumour DNA, ctDNA.) Dynamics From Patients With ER+, HER2- Advanced Breast Cancer in the Phase 3 EMBER-3 Trial [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD5-08.","DOI":"10.1158\/1557-3265.SABCS25-PD5-08"},{"key":"1808_CR5","doi-asserted-by":"crossref","unstructured":"Andre F, Fasching PA, Prat A, Neven P, Lu Y, Bardia A, Curigliano G, Kaklamani V, Razavi P, Yap Y, Su F, Roux E, Pantoja K, Wu J, Lteif A, Juric D. Pooled analysis of patients (pts) treated with 1st-line (1L) ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) studies: long-term progression-free survival (PFS) [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium. 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD5-10.","DOI":"10.1158\/1557-3265.SABCS25-PD5-10"},{"key":"1808_CR6","doi-asserted-by":"crossref","unstructured":"Llombart-Cussac A, P\u00e9rez-Garc\u00eda J, Ruiz-Borrego M, Stradella A, Bermejo B, Escriv\u00e1-de-Roman\u00ed S, Reboredo C, Ribelles N, Cort\u00e9s-Salgado A, Albacar C, Colleoni M, Antonarelli G, Notini G, Gion M, Garc\u00eda-Mosquera J, Sanz L, Mart\u00ednez-Garc\u00eda E, Gonz\u00e1lez-Alonso P, Amaya-Garrido A, Guerrero J, Rodr\u00edguez-Morat\u00f3 J, Mina L, Martrat G, Quintana M, Riva F, Dustin D, Zhang H, Mancino M. J. Cort\u00e9s. Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr GS1-06.","DOI":"10.1158\/1557-3265.SABCS25-GS1-06"},{"issue":"4 Suppl","key":"1808_CR7","first-page":"AbstractnrRF4","volume":"32","author":"M Balic","year":"2026","unstructured":"Balic M, Tang G, Young G, Rastogi P, Acosta J, Schneeweiss A, Hilton C, Freeman T, Denkert C, Reinisch M, Palomares MR, Bradley AA, Murali S, Boileau J, Boudreau D, Polewski PJ, Hassan S, Mouta J, Darbonne WC, Baehner FL, Mamounas EP, Wolmark N, Loibl S, Geyer Jr. CE. Evaluation of a whole-exome sequencing tumor-informed circulating tumor DNA MRD assay in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without atezolizumab: A prospective sub study of the NSABP-B59\/GBG-96-GeparDouze Trial [abstract]. Clin Cancer Res. 2026;32(4 Suppl):AbstractnrRF4\u201303. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR;.","journal-title":"Clin Cancer Res"},{"key":"1808_CR8","doi-asserted-by":"crossref","unstructured":"Parsons HA, Ballman K, Heitzer E, Watson M, Balic M, Hlauschek D, Renner D, Kalashnikova E, Steger G, Balko JM, Novik Y, Martin M, Rodriguez AA, Dayao Z, Chan A, Nili Gal-Yam E, Liu MC, Isaacs C, Los M, Gil Gil M, Felder B, Denkert C, Fasching P, Liu F, O\u2019Donnell T, Mayer EL, Gnant M, Symmans WF. A. DeMichele. Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr RF3-04.","DOI":"10.1158\/1557-3265.SABCS25-RF3-04"},{"key":"1808_CR9","doi-asserted-by":"crossref","unstructured":"Cunningham N, Cutts RJ, Swift C, Dunne K, Dewan M, Kilburn L, Goddard K, Hall P, Harper-Wynne C, Hickish T, Macpherson I, Okines A, Wardley A, Waters S, Palmieri C, Winter M, Bliss J, Dustin D, Ellis M, Garcia- Murillas I. N. C. Turner. Tissue-free circulating tumour DNA detection in patients with early triple negative breast cancer from the c-TRAK-TN trial [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr RF3-05.","DOI":"10.1158\/1557-3265.SABCS25-RF3-05"},{"issue":"4 Suppl","key":"1808_CR10","first-page":"AbstractnrPD5","volume":"32","author":"A J. Medford","year":"2026","unstructured":"J. Medford A, Scalise C, Dhulekar S, Smolar Z, Niemierko A, Kalashnikova E, Rodriguez A, Spring LM, Kim J, Comander A, Rosenstock A, Peppercorn JM, Shin JA, Schnipper L, Benjamin H, Isakoff SJ, Ellisen LW, Juric D, Moy B, Liu MC, Aleshin A, Bardia A. Personalized circulating tumor DNA (ctDNA) testing, intervention, and temporal dynamics in ER+\/HER2- early-stage breast cancer (LEADER). Clin Cancer Res. 2026;32(4 Suppl):AbstractnrPD5\u201301. [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR;.","journal-title":"Clin Cancer Res"},{"key":"1808_CR11","doi-asserted-by":"crossref","unstructured":"Elliott MJ, Amir E, Nadler MB, Li M, Yu C, Audoin M, Putcha G, Levin W, Birke\u00e4l S, Howarth K, Bedard P, Siu LL, Berman H, Townsley C, Wu M. D. W. Cescon. Capecitabine for Targeted Eradication of aRising ctDNA Molecular Residual Disease in ER-positive\/HER2-negative Early-stage Breast Cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9\u201312; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS5-09-28.","DOI":"10.1158\/1557-3265.SABCS25-PS5-09-28"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01808-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01808-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01808-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T22:55:41Z","timestamp":1780008941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01808-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1808"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01808-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cynthia Ma: consulting fees from Merck, Regor Therapeutics, AstraZeneca, Novartis, Stemline, Eli Lilly, Delphi Diagnostics, Biovica, FoRx Therapeutics, Tempus, Bayer, Pfizer, Puma, Pathlight, Genentech, Funding: Pfizer. Shridar Ganesan: consulting fees from Merck, EMD Serano, Eikon, Foghorn Rx, Lunit, ConstInt Rx, KayoThera. SG has received research funding from Tempus, Gandeeva Rx, M2GEN. SG\u2019s spouse is an employee of Merck and has equity in Merck. Neil Vasan: Consulting fee from Apertor Therapeutics, Avenzo Therapeutics, Expert Connect, GLG, Guidepoint Global, Horizon CME, MJH Healthcare, Regor Therapeutics; Honoraria: Gilead, Susan G. Komen, University of Texas Health Sciences Center; Royalties: Wolters Kluwer; Travel: Gilead; Scientific Advisory Board: Meliora Therapeutics. Douglas Marks: Consultant\/Advisory: Astrazeneca, Biotheranostics, Gilead, Lilly, OncLive\/MJH, Seattle Genetics, Stemline\/Menarini, Daiichi, Ideology, Sponsored Research: Agendia, Merck. Other authors: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}